Cite

HARVARD Citation

    Salas, Q. et al. (n.d.). Effective treatments are required for patients with diffuse large B‐cell lymphoma (DLBCL) with primary refractory disease. Hematological oncology. p. 344. [Online]. 
  
Back to record